secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2025-07-09T23:59:59+00:00
Accession:  0001213900-25-062192
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell Q2 2025 preliminary sales up 18% YoY to $6.4M; backlog cleared
-----------------------------------------------------------------------

- Preliminary Q2 2025 product sales $6.4M, up 18% from $5.5M in Q2 2024.
- Twelve-month sales ended June 30, 2025 were $28.3M, up 22% YoY from $23.2M.
- Order backlog reduced to under $100k as of June 30, 2025, down from $3.4M on May 6.
- Evaluating additional capacity investments to increase production capacity to ~$40M per year.
- Conference call scheduled for August 15, 2025 to discuss full Q2 2025 financial results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000121390025062192/0001213900-25-062192-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000121390025062192/ea0248347-8k_immucell.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-062192

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer